Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept (Tai Ai) in Primary Sjögren's Syndrome
CTR20223429Phase 3Completed
- Sponsor
- Rongchang Pharmaceuticals
- Start
- Dec 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in primary Sjögren's syndrome, sponsored by Rongchang Pharmaceuticals. Started Dec 2022; status: completed.
02
Drugs
telitacicept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on CTR20223429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223429.